Ligand Enters Into Worldwide OmniAb Platform License Agreement with Sanofi

Advised Ligand Pharmaceuticals in a worldwide OmniAb license agreement with Sanofi.  Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform. 

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. OmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic antibodies.